LakeShore Biopharma Co Gross Profit

LakeShore Biopharma Co posts a gross profit of $250M as of March 2024. That compares with $42M in the prior-year period — up 505.0% year over year. That is below the sector sector average of $750M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, LakeShore Biopharma Co's gross profit was $42M. The latest reading is $250M — a 505.0% year-over-year increase (period ending March 2024). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a gross profit near $750M is typical. LakeShore Biopharma Co's $250M is lower that level. That is roughly 66.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of LakeShore Biopharma Co's financial statement story. At $250M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LSB's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $750M), and (3) consistency with growth and profitability. This page covers the first two; LakeShore Biopharma Co's other metric pages and overview cover the third.